IMAGENEBIO INC
IMANASDAQ🏆 #4297 by market capUS Equity
——
Quote unavailableTrack IMA
Get earnings, price moves & breaking news on Telegram
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$48M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
5.2x
Fair
Otter Score
—
Insufficient data
No chart data available for IMA.
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $3.88 – $9.10
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 11.3M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $800,000
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 5.2x
- EPS (TTM)
- $-5.34
- Dividend Yield
- —
- Dilution (1yr)
- +693.1%
IMAGENEBIO INC
IMAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$800K▼ −77.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-29.1%▼ −151.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$48M▲ +30.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$48M▲ +4.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.2M▲ +693.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$25M▼ −$7M YoY
StockOtter · stockotter.spaceAbout IMAGENEBIO INC
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.